LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aktien・Arvinas Inc

Arvinas Inc

Geschlossen

BrancheGesundheitswesen

7.69 0.13

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.6899999999999995

Max

7.89

Schlüsselkennzahlen
By Trading Economics
Einkommen	9.8M -58M
Verkäufe	6.1M 16M
EPS	-0.9
Gewinnspanne	-369.231
Angestellte	246
EBITDA	4.4M -62M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+90.78% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-70M 554M
Vorheriger Eröffnungskurs	7.56
Vorheriger Schlusskurs	7.69

Nachrichtenstimmung

By Acuity

33%

67%

84 / 344 Ranking in Healthcare

Arvinas Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Juni 2026, 21:51 UTC

Wichtige Markttreiber

Merlin Shares Rally After Defense Department's Design Review Wraps

4. Juni 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4. Juni 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4. Juni 2026, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4. Juni 2026, 23:41 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia to Enter Trading Halt

4. Juni 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Juni 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4. Juni 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4. Juni 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4. Juni 2026, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4. Juni 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4. Juni 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4. Juni 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4. Juni 2026, 18:47 UTC

Akquisitionen, Fusionen, Übernahmen

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4. Juni 2026, 18:38 UTC

Ergebnisse

Money Quote: Tech Weakness in Context -- WSJ

4. Juni 2026, 18:24 UTC

Ergebnisse

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4. Juni 2026, 16:58 UTC

Ergebnisse

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4. Juni 2026, 16:38 UTC

Ergebnisse

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4. Juni 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4. Juni 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4. Juni 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer-Vergleich

Kursveränderung

Arvinas Inc Prognose

Kursziel

By TipRanks

90.78% Vorteil

12-Monats-Prognose

Durchschnitt 14.69 USD 90.78%

Hoch 24 USD

Tief 6 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arvinas Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Arvinas Inc – Dist abgegeben haben.

Stimmung

By Acuity

84 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.